Girdhari Lal, Ph.D.

Dr. Girdhari Lal is a SeniorScientist working at National Center for Cell Science (NCCS), Pune. Dr. Lal obtained his PhD degree from Indian Institute of Science, Bangalore in the year 2005. He was Assistant Professor at Mount Sinai School of Medicine, New York City, USA, before he returned to India in the year 2010. Dr. Lal’s Laboratory is interested in understanding the cellular and molecular mechanism of immune tolerance.

He has published more than 49 peer reviewed high impact factor journals such as Nature Immunology, Immunity, Blood, Journal of Autoimmunity, Oncoimmunology, Journal for Immunotherapy of Cancer, Journal of Immunology, and International Journal of Cancer. He also presented his work in more than 150 National and International meetings and also written two book chapters in immunology.

            Dr. Lal also received Ramalingaswami Fellowship, Innovative Young Biotechnologist Award from Department of Biotechnology, Government of India, and SwarnJayanti Fellowship from Department of Science and Technology, Government of India.He is founder Executing council member of Society of Inflammation Research as well Immuno-Oncology Society of India. Currently, Dr. Lal is also Vice President (West Zone) ofIndian Immunology Society, and also member of several National and International Immunology Society.


ABSTRACT

Mechanisms of Immunopathogenesis in Cancer

Immunosurveillance is a complex process by which a transformed or cancerous cells are continuously recognized and removed from the body. The molecular mechanism of tumor survival involves modifying tumor microenvironments such as loss or downregulation of MHC class I antigen, defective death receptor signaling, lack of co-stimulatory signals, and the presence of immunosuppressive cytokines, induction of apoptosis of activated T cells, and presence of regulatory immune cells. I will discuss how different cells and molecules interact with each other and participate in immunoediting and how these mechanisms form a potential therapeutic target to promote anti-tumor immunity.